Literature DB >> 8500302

Design, methods, and conduct of the Optic Neuritis Treatment Trial.

P A Cleary1, R W Beck, M M Anderson, D J Kenny, J Y Backlund, P R Gilbert.   

Abstract

The Optic Neuritis Treatment Trial (ONTT) was an investigator-initiated, multi-centered, randomized, controlled clinical trial supported by cooperative agreements and grants. It was designed to evaluate the efficacy and safety of oral prednisone or intravenous methylprednisolone followed by oral prednisone as compared with oral placebo. The primary outcome measures were contrast sensitivity and visual field; secondary measures were visual acuity and color vision. Four hundred fifty-seven patients were followed for a minimum of 6 months and a maximum of 3 years. This article describes the design and the methods used to implement the ONTT.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8500302     DOI: 10.1016/0197-2456(93)90015-6

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  18 in total

Review 1.  Disease-modifying therapy in MS: a critical review of the literature. Part I: Analysis of clinical trial errors.

Authors:  Douglas S Goodin
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 2.  Corticosteroids for treating optic neuritis.

Authors:  Robin L Gal; Satyanarayana S Vedula; Roy Beck
Journal:  Cochrane Database Syst Rev       Date:  2015-08-14

Review 3.  Corticosteroids for treating optic neuritis.

Authors:  S S Vedula; S Brodney-Folse; R L Gal; R Beck
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

4.  Management of optic neuritis.

Authors:  Vimla Menon; Rohit Saxena; Ruby Misra; Swati Phuljhele
Journal:  Indian J Ophthalmol       Date:  2011 Mar-Apr       Impact factor: 1.848

5.  Correlation of quality of life with clinical symptoms and signs at the time of glaucoma diagnosis.

Authors:  R P Mills
Journal:  Trans Am Ophthalmol Soc       Date:  1998

Review 6.  Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection.

Authors:  Reiko E Sakai; Daniel J Feller; Kristin M Galetta; Steven L Galetta; Laura J Balcer
Journal:  J Neuroophthalmol       Date:  2011-12       Impact factor: 3.042

Review 7.  Corticosteroids for treating optic neuritis.

Authors:  Robin L Gal; Satyanarayana S Vedula; Roy Beck
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

8.  Color vision impairment in multiple sclerosis points to retinal ganglion cell damage.

Authors:  E J Lampert; M Andorra; R Torres-Torres; S Ortiz-Pérez; S Llufriu; M Sepúlveda; N Sola; A Saiz; B Sánchez-Dalmau; P Villoslada; Elena H Martínez-Lapiscina
Journal:  J Neurol       Date:  2015-08-11       Impact factor: 4.849

9.  Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up.

Authors: 
Journal:  Arch Neurol       Date:  2008-06

10.  Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial.

Authors:  Roy W Beck; Robin L Gal
Journal:  Arch Ophthalmol       Date:  2008-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.